US 11,673,893 B2
CDK inhibitors and their use as pharmaceuticals
Liang Lu, Wilmington, DE (US); Rupa Shetty, Wilmington, DE (US); Andrew Paul Combs, Wilmington, DE (US); Chaofeng Dai, Wilmington, DE (US); Raul Andrew Leal, Wilmington, DE (US); and Klare Lazor Bersch, Wilmington, DE (US)
Assigned to Prelude Therapeutics Incorporated, Wilmington, DE (US)
Filed by Prelude Therapeutics Incorporated, Wilmington, DE (US)
Filed on Sep. 11, 2020, as Appl. No. 17/18,005.
Claims priority of provisional application 63/005,577, filed on Apr. 6, 2020.
Claims priority of provisional application 62/898,839, filed on Sep. 11, 2019.
Prior Publication US 2021/0070761 A1, Mar. 11, 2021
Int. Cl. C07D 487/04 (2006.01); C07D 401/08 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 401/14 (2006.01); C07D 417/08 (2006.01); C07D 413/14 (2006.01); A61P 35/00 (2006.01); C07D 401/04 (2006.01); C07D 405/14 (2006.01); C07D 417/04 (2006.01); C07D 498/04 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/00 (2018.01); C07D 401/04 (2013.01); C07D 401/08 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/04 (2013.01); C07D 417/08 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 498/04 (2013.01)] 10 Claims
 
1. A compound of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof.